Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02929823 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
A Phase 2 study, sponsored by Senju Pharmaceutical Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT02929823: Completed Phase 2 study, sponsored by Senju Pharmaceutical Co..
NCT02929823 is a Phase 2 study that has completed, run by Senju Pharmaceutical Co.. The registered enrollment target is 130 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02929823, a Phase 2 study, has completed, sponsored by Senju Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
Primary Outcome
A patient will be considered a success for clearing of corneal fluorescein staining if their fluorescein staining has disappeared
Interventions
- DRUG High Dose SJP-0035 Ophthalmic Solution
- DRUG Low Dose SJP-0035 Ophthalmic Solution
- DRUG Vehicle of SJP-0035 Ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-05-03 |
| Phase | Phase 2 |
What the finished NCT02929823 record still lists
NCT02929823 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which High Dose SJP-0035 Ophthalmic Solution is the first listed.
NCT02929823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02929823 about?
NCT02929823 is a clinical study titled "Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders". The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
What is the current status of trial NCT02929823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2016-09. Estimated completion is 2017-05-03.
What interventions are being tested in trial NCT02929823?
The interventions under investigation include: High Dose SJP-0035 Ophthalmic Solution (DRUG), Low Dose SJP-0035 Ophthalmic Solution (DRUG), Vehicle of SJP-0035 Ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02929823?
This trial is sponsored by Senju Pharmaceutical Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02929823's enrollment target sits among peer trials
130 543rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia